MERS-CoV

MERS-CoV

Biodefense Headlines – 31 March 2025

Biosecurity March 31, 2025

This week’s topics include restructuring of ASPR, anti-vaccine leadership at NIH, the UK’s new pathogen priority research targets list, and data on a post-exposure treatment for filoviruses. FEATURED Trump Administration…

MERS-CoV: Clinical Trial Starts for Regeneron’s Monoclonal Antibody Treatments

Experimental MERS Antibody Therapeutics Enter Clinical Trial

WHO Updates Blueprint List of Priority Diseases

New Coalition for Epidemic Preparedness Sets Sights on MERS-CoV, Lassa and Nipah

Turnkey Detection: Rapid Diagnostics in the Field

BARDA Backs Antibody Therapy Against MERS Virus

First-In-Human Study of MERS Vaccine Completes Enrollment

NIH Evaluating New Antibody Treatment for MERS-CoV

MERS-CoV Less Virulent During Outbreak?

MERS-CoV Likely Began in Bats, Moved to Camels, Then People

Walter Reed Kicks Off Phase 1 MERS Vaccine Trial

Inovio and GeneOne Kick Off MERS Vaccine Trial

Report Outlines Framework for Global Pandemic Preparedness

New Vaccine Against MERS Tested on Dromedary Camels

World Vaccine Congress 2016

PHEMCE Medical Countermeasure Stakeholders Workshop

Rapid Medical Countermeasure Response to Infectious Diseases

Kenya: MERS Virus Widespread in Camels

IVI Initiates MERS Vaccine Research and Development

Positive Results for MERS Vaccine in Monkeys and Camels

Biodefense Headlines – 31 March 2025